Cargando…

Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma

Detalles Bibliográficos
Autores principales:	Kuhnl, Andrea, Roddie, Claire, Kirkwood, Amy A., Menne, Tobias, Cuadrado, Maria, Marzolini, Maria A. V., Osborne, Wendy, Sanderson, Robin, O’Reilly, Maeve, Townsend, William, Benjamin, Reuben, Potter, Victoria, Patten, Piers E. M., Yallop, Deborah, Voo, Stefan, Petrides, George S., Mulholland, Nicola, Kayani, Irfan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753214/ https://www.ncbi.nlm.nih.gov/pubmed/34700342 http://dx.doi.org/10.1182/bloodadvances.2021005807

Ejemplares similares

Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma
por: Roddie, Claire, et al.
Publicado: (2023)

Lymphocyte morphology in a patient receiving CD19 chimeric antigen receptor T‐cell therapy for mantle cell lymphoma
por: Marzolini, Maria A. V., et al.
Publicado: (2021)

P1169: ELEVATED CRP AT INFUSION OF AXICABTAGENE CILOLEUCEL PREDICTS HIGH-GRADE CAR-T TOXICITY AND OUTPERFORMS MORE COMPLEX SCORES
por: Boyle, S., et al.
Publicado: (2022)

Human Herpesvirus 6 Encephalitis Following Axicabtagene Ciloleucel Treatment for Refractory Diffuse Large B Cell Lymphoma
por: Shah, Mili, et al.
Publicado: (2021)

Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy following anti‐CD19 CAR‐T therapy: a case report
por: Mackenzie, Strachan, et al.
Publicado: (2021)

Fludarabine-Melphalan-Campath, Followed by Unmanipulated Peripheral-Blood Haematopoietic Stem Cells, Can Still Cure Lymphoma
por: Avenoso, Daniele, et al.
Publicado: (2023)

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
por: Roddie, Claire, et al.
Publicado: (2023)

Correction to: ICU-outcomes in CAR-T patients—A single centre experience
por: Materski, T., et al.
Publicado: (2021)

CD34(+)-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy
por: Mullanfiroze, Khushnuma, et al.
Publicado: (2022)

The architecture of neoplastic follicles in follicular lymphoma; analysis of the relationship between the tumor and follicular helper T cells
por: Townsend, William, et al.
Publicado: (2020)

Online synchronous chat counselling for young people aged 12–25: a mixed methods systematic review protocol
por: Tibbs, Maria, et al.
Publicado: (2022)

Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma
por: Graham, Charlotte Elizabeth, et al.
Publicado: (2021)

A qualitative service evaluation of patient and caregiver experiences of CAR-T therapy: Recommendations for service development and implications for palliative care teams
por: Stenson, Charlotte L, et al.
Publicado: (2022)

Evolution of (18)F-FDG PET/CT Findings in Patients After COVID-19: An Initial Investigation
por: Thornton, Andrew, et al.
Publicado: (2022)

CAR T Cell Therapy–Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity?
por: Ghosh, Arjun K., et al.
Publicado: (2020)

P1460: SAFETY AND EFFICACY FINDINGS OF AUTO1, A FAST-OFF RATE CD19 CAR, IN RELAPSED/REFRACTORY PRIMARY CNS LYMPHOMA
por: Roddie, C., et al.
Publicado: (2022)

P1459: SAFETY AND EFFICACY FINDINGS OF AUTO1, A FAST-OFF RATE CD19 CAR, IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA (B-NHL), AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) / SMALL LYMPHOCYTIC LYMPHOMA (SLL)
por: Roddie, C., et al.
Publicado: (2022)

Hybrid FDG-PET/MR imaging of chronic osteomyelitis: a prospective case series
por: Hulsen, Dennis Jan Willem, et al.
Publicado: (2019)

Impact of car transport availability and drive time on eye examination uptake among adults aged ≥60 years: a record linkage study
por: Wright, David M, et al.
Publicado: (2019)

Language dysfunction-associated EEG findings in patients with CAR-T related neurotoxicity
por: Sokolov, Elisaveta, et al.
Publicado: (2020)

Allogeneic CAR-T Cells: More than Ease of Access?
por: Graham, Charlotte, et al.
Publicado: (2018)

Aortic (18)F-FDG uptake in patients suffering from granulomatosis with polyangiitis
por: Kemna, Michael J., et al.
Publicado: (2015)

Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
por: Roddie, Claire, et al.
Publicado: (2021)

Does quantification have a role to play in the future of bone SPECT?
por: Ross, James C., et al.
Publicado: (2019)

The expansion of targetable biomarkers for CAR T cell therapy
por: Townsend, Michelle H., et al.
Publicado: (2018)

Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT
por: Breen, William G., et al.
Publicado: (2022)

Pharmacokinetic modeling of [(18)F]fluorodeoxyglucose (FDG) for premature infants, and newborns through 5-year-olds
por: Khamwan, Kitiwat, et al.
Publicado: (2016)

S262: SAFETY AND EFFICACY OF OBECABTAGENE AUTOLEUCEL (OBE-CEL), A FAST-OFF RATE CD19 CAR IN RELAPSED/REFRACTORY ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA:TOP LINE RESULTS OF THE PIVOTAL FELIX STUDY
por: Roddie, Claire, et al.
Publicado: (2023)

Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL
por: Northend, Michael, et al.
Publicado: (2022)

Impact of combined (18)F-FDG PET/CT in head and neck tumours
por: Syed, R, et al.
Publicado: (2005)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors
por: Johnson, Abigail, et al.
Publicado: (2022)

Techno-economic data for a multi-model approach to decarbonisation of the Irish private car sector
por: Mulholland, Eamonn, et al.
Publicado: (2017)

Inflammatory reactions mimic residual or recurrent lymphoma on [(18)F]FDG-PET/CT after CD19-directed CAR T-cell therapy
por: de Boer, Janneke W., et al.
Publicado: (2023)

318 Building A Better CAR: Improving CAR-T Trafficking in Cancer Therapy
por: Hong, Yeonsun, et al.
Publicado: (2022)

Explosion investigation
por: Yallop, H John
Publicado: (1980)

AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survival
por: Mehra, Vedika, et al.
Publicado: (2023)

Tunable control of CAR T cell activity through tetracycline mediated disruption of protein–protein interaction
por: Hotblack, Alastair, et al.
Publicado: (2021)

Trigeneration: Possibilities of Implementation at CERN
por: Kühnl-Kinel, J
Publicado: (1999)

New age water chillers with water as refrigerant
por: Kühnl-Kinel, J
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_1oanpto6c227n5k89t2joejvaa